Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7845416rdf:typepubmed:Citationlld:pubmed
pubmed-article:7845416lifeskim:mentionsumls-concept:C0004030lld:lifeskim
pubmed-article:7845416lifeskim:mentionsumls-concept:C0085082lld:lifeskim
pubmed-article:7845416lifeskim:mentionsumls-concept:C0085979lld:lifeskim
pubmed-article:7845416lifeskim:mentionsumls-concept:C0064113lld:lifeskim
pubmed-article:7845416lifeskim:mentionsumls-concept:C0205281lld:lifeskim
pubmed-article:7845416lifeskim:mentionsumls-concept:C0018270lld:lifeskim
pubmed-article:7845416lifeskim:mentionsumls-concept:C0521033lld:lifeskim
pubmed-article:7845416lifeskim:mentionsumls-concept:C1517004lld:lifeskim
pubmed-article:7845416pubmed:issue3-4lld:pubmed
pubmed-article:7845416pubmed:dateCreated1995-3-9lld:pubmed
pubmed-article:7845416pubmed:abstractTextThe guinea pig model of experimental aspergillosis was used to evaluate the efficacy of itraconazole 2.5 and 5 mg kg-1 in preventing the invasive phase of the disease when animals were already loaded with Aspergillus conidia. Evaluations were made by recording the survival rates, culturing fragments of nine organs, examining seven organs by means of histochemistry and immunohistochemistry (mAb EB-A1 to Aspergillus galactomannan) and by serological titration of galactomannan. The data indicate that itraconazole is highly effective in preventing true invasive aspergillosis. Serological evaluations of antigenaemia suggest that low titres may only reflect fungaemia, while titres of 1:8 and above are suggestive of invasive disease.lld:pubmed
pubmed-article:7845416pubmed:languageenglld:pubmed
pubmed-article:7845416pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7845416pubmed:citationSubsetIMlld:pubmed
pubmed-article:7845416pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7845416pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7845416pubmed:statusMEDLINElld:pubmed
pubmed-article:7845416pubmed:issn0933-7407lld:pubmed
pubmed-article:7845416pubmed:authorpubmed-author:PiérardG EGElld:pubmed
pubmed-article:7845416pubmed:authorpubmed-author:Van CutsemJJlld:pubmed
pubmed-article:7845416pubmed:authorpubmed-author:DelvennePPlld:pubmed
pubmed-article:7845416pubmed:authorpubmed-author:Piérard-Franc...lld:pubmed
pubmed-article:7845416pubmed:authorpubmed-author:ArreseJ EJElld:pubmed
pubmed-article:7845416pubmed:issnTypePrintlld:pubmed
pubmed-article:7845416pubmed:volume37lld:pubmed
pubmed-article:7845416pubmed:ownerNLMlld:pubmed
pubmed-article:7845416pubmed:authorsCompleteYlld:pubmed
pubmed-article:7845416pubmed:pagination117-22lld:pubmed
pubmed-article:7845416pubmed:dateRevised2003-11-14lld:pubmed
pubmed-article:7845416pubmed:meshHeadingpubmed-meshheading:7845416-...lld:pubmed
pubmed-article:7845416pubmed:meshHeadingpubmed-meshheading:7845416-...lld:pubmed
pubmed-article:7845416pubmed:meshHeadingpubmed-meshheading:7845416-...lld:pubmed
pubmed-article:7845416pubmed:meshHeadingpubmed-meshheading:7845416-...lld:pubmed
pubmed-article:7845416pubmed:meshHeadingpubmed-meshheading:7845416-...lld:pubmed
pubmed-article:7845416pubmed:meshHeadingpubmed-meshheading:7845416-...lld:pubmed
pubmed-article:7845416pubmed:meshHeadingpubmed-meshheading:7845416-...lld:pubmed
pubmed-article:7845416pubmed:meshHeadingpubmed-meshheading:7845416-...lld:pubmed
pubmed-article:7845416pubmed:meshHeadingpubmed-meshheading:7845416-...lld:pubmed
pubmed-article:7845416pubmed:articleTitleExperimental aspergillosis in guinea pigs: influence of itraconazole on fungaemia and invasive fungal growth.lld:pubmed
pubmed-article:7845416pubmed:affiliationDepartment of Dermatopathology, University of Liège, Belgium.lld:pubmed
pubmed-article:7845416pubmed:publicationTypeJournal Articlelld:pubmed